血脂康对高脂血症患者血脂谱的作用和对血栓素A_2与前列环素的影响

The effects of Xuezhikang on serum lipid profile, thromboxane A_2 and prostacyclin in patients with hyperlipoidemia

目的 研究血脂康对高脂血症患者血脂的调脂作用及对血栓素A2 (TXA2 )、前列环素(PGI2 )的影响。方法 91例原发性高脂血症患者随机分为血脂康组和吉非罗齐对照组 ,分别口服血脂康 1.2g/d或吉非罗齐 1.2g/d ,连服 8周 ,治疗前后测定血脂谱、TXB2 、6 酮 前列腺素F1α( 6 Keto PGF1α)。结果 ( 1)服血脂康和吉非罗齐 8周后 ,血清总胆固醇 (TC)分别降低 2 1.6%和 2 0 .4 % ,甘油三酯 (TG)分别降低 2 3 .3 %和 4 0 .3 % ,低密度脂蛋白胆固醇 (LDL C)分别降低 3 3 .3 %和 2 4 .8% ,高密度脂蛋白胆固醇 (HDL C)分别升高 3 3 .7%和 2 6.9% (以上P均 <0 0 1) ,血脂康降低TG的作用弱于吉非罗齐 (P <0 .0 5 ) ,而其降低TC、LDL C和升高HDL C的作用与吉非罗齐比较差异无显著性 (P均 >0 0 5 )。 ( 2 )血脂康可使血浆脂蛋白 (a) [LP(a) ]含量降低 2 8.2 % (P <0 .0 1) ,而吉非罗齐仅降低 4 .9%(P >0 .0 5 ) ;血脂康的作用强于吉非罗齐 (P <0 .0 1)。 ( 3 )血脂康和吉非罗齐使血浆TXB2 含量分别降低 3 4.2 %和 8.4 % (P均 <0 .0 1) ,而且血脂康的作用强于吉非罗齐 (P <0 .0 1) ;血脂康和吉非罗齐使血浆 6 Keto PGF1α含量分别升高 65 .4 %和 11.7% (P均 <0 .0 1) ,血脂康的作用强于吉非罗齐 (P <0 .0 1)。

Objective To study the effects of Xuezhikang on lipid profile, thromboxane(TX) A 2、prostacyclin(PGI 2) in patients with hyperlipoidemia. Methods 91 patients with hyperlipoidemia were randomly divided into a treatment group ( n =47, Xuezhikang 1.2 g/d Bid, p.o) and control group ( n =44, gemfibrozil 1.2 g/d Bid, p.o). serum lipids、TXB 2 and 6 Keto PGF 1α were determined before and 8 weeks after the treatment. Results (1)After 8 weeks of treatment, the level of serum total cholesterol (TC) and low density lipoprotein cholesterol (LDL C) decreased by 21.6% ( P <0.01) and 33.3% ( P <0. 01) in the Xuezikang group and by 20.4% ( P <0.01) and 24.8%( P <0.01) in the gemfibrozil group respectively. Serum high density lipoprotein cholesterol (HDL C) level elevated by 33.7% in the Xuezhikang group ( P <0.01) and 26.9% in the gemfibrozil group ( P <0.01). The effect of Xuezhikang was the same as gemfibrozil. There was no statistically significant difference between the effects of these two drugs. Triglyceride(TG) level decreased by 23.3% in the Xuezhikang group ( P <0.01) and 40.3% in the gemfibrozil group( P <0.01).TG lowering effect of gemfibrozil was superior to that of Xuezhikang ( P <0.05). (2)The level of lipoprotein (a) [LP(a)] in the plasma decreased by 28.2%( P <0.01) in the Xuezhikang group and by 4.9%( P >0.05) in the gemfibrozil group.LP(a) lowering effect of Xuezhikang was superior to that of gemfibrozil( P <0.01). (3)The Level of thromboxane (TX) B 2 in the plasma decreased by 34.2% in the Xuezhikang group ( P <0.01) and by 8.4% in the gemfibrozil group ( P <0.01). TXB 2 lowering effect of Xuezhikang was superior to that of gemfibrozil( P <0.01). The level of 6 KetO PGF 1α in the plasma elevated by 65.4% in the Xuezhikang group( P <0.01) and by 11.7% in the gemfibrozil group ( P <0.01);the effect of Xuezhikang was superior to that of gemfibrozil( P <0.01). Conclusion Xuezhikang could markedly decrease the level of TC and LDL C and elevate that of HDL C in patients with hyperlipoidemia and the effects of Xuezhikang were the same as those of gemfibrozil.TG lowering effect of gemfibrozil was superior to that of Xuezhikang, but Xuezhikang could markedly decrease the level of Lp(a) and regluate the balance between TXA 2and PGI 2, its effect being superior to that of gemfibrozil.